Recent advances on cellular therapies and immune modulators for graft-versus-host disease

Expert Rev Clin Immunol. 2014 Oct;10(10):1357-74. doi: 10.1586/1744666X.2014.955475. Epub 2014 Sep 8.

Abstract

The efficacy of allogeneic hematopoietic stem cell transplantation is counterbalanced by the occurrence of life-threatening immune-mediated complications, such as graft-versus-host disease (GVHD), a multistep disease which is reportedly fatal to approximately 15% of transplant recipients. It is now established that T-cell-dendritic cell interactions, T-cell activation, release of proinflammatory cytokines and T-cell trafficking partake in GVHD pathogenesis. This article will focus on the most recent strategies aimed at preventing/treating GVHD by manipulating components of the innate and adaptive immune response from both the donor and the host.

Keywords: Treg; bone marrow microenvironment; cytokines; dendritic cells; hematopoietic stem cell transplantation; immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Graft vs Host Disease / immunology*
  • Graft vs Host Disease / prevention & control*
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Humans
  • Transplantation Immunology / immunology*